Literature DB >> 15793108

Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.

Sutep Jaruratanasirikul1, Somchai Sriwiriyajan, Jarurat Punyo.   

Abstract

The time that concentrations in serum are above the MIC (T>MIC) is the pharmacokinetic/pharmacodynamic parameter correlating with the therapeutic efficacy of beta-lactam antibiotics. The aim of this study was to demonstrate the T>MIC of meropenem when administered by a 3-h infusion compared with that when administered by bolus injection. The study was conducted with nine patients with ventilator-associated pneumonia. Each subject received meropenem in three regimens consecutively: (i) bolus injection of 1 g every 8 h for 24 h; (ii) 3-h infusion of 1 g every 8 h for 24 h; and (iii) 3-h infusion of 2 g every 8 h for 24 h. Following bolus injection, the percentages of the T>MICs of 16, 8, 4, and 1 microg/ml were 28.33% +/- 11.67%, 45.89% +/- 22.90%, 57.00% +/- 24.82%, and 74.67% +/- 17.94% of an 8-h interval, respectively. For the 3-h infusion of 1 g of meropenem, the percentages of the T>MICs of 16, 8, 4, and 1 microg/ml were 37.78% +/- 20.57%, 58.11% +/- 24.38%, 72.67% +/- 21.97%, and 93.56% +/- 6.84% of an 8-h interval, respectively. For the 3-h infusion of 2 g of meropenem, the percentages of the T>MICs of 16, 8, 4, and 1 microg/ml were 57.89% +/- 24.26%, 72.89% +/- 22.40%, 85.56% +/- 16.42%, and 98.56% +/- 3.28% of an 8-h interval, respectively. In conclusion, a 3-h infusion resulted in greater T>MICs than those after a bolus injection. For the treatment of infections caused by pathogens with intermediate resistance, a 3-h infusion of 2 g of meropenem every 8 h can provide concentrations in serum above the MIC of 16 microg/ml for almost 60% of an 8-h interval.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15793108      PMCID: PMC1068632          DOI: 10.1128/AAC.49.4.1337-1339.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.

Authors:  Prachi K Dandekar; Dana Maglio; Christina A Sutherland; Charles H Nightingale; David P Nicolau
Journal:  Pharmacotherapy       Date:  2003-08       Impact factor: 4.705

2.  Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.

Authors:  Sutep Jaruratanasirikul; Somchai Sriwiriyajan
Journal:  J Antimicrob Chemother       Date:  2003-08-13       Impact factor: 5.790

3.  Antimicrobial resistance issues of the future.

Authors:  W A Craig
Journal:  Diagn Microbiol Infect Dis       Date:  1996-08       Impact factor: 2.803

4.  A rapid, sensitive high performance liquid chromatographic method for the determination of meropenem in pharmaceutical dosage form, human serum and urine.

Authors:  Y Ozkan; I Küçükgüzel; S A Ozkan; H Y Aboul-Enein
Journal:  Biomed Chromatogr       Date:  2001-06       Impact factor: 1.902

Review 5.  Meropenem: a review of its use in patients in intensive care.

Authors:  M Hurst; H M Lamb
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

6.  Continuous infusion versus intermittent administration of meropenem in critically ill patients.

Authors:  F Thalhammer; F Traunmüller; I El Menyawi; M Frass; U M Hollenstein; G J Locker; B Stoiser; T Staudinger; R Thalhammer-Scherrer; H Burgmann
Journal:  J Antimicrob Chemother       Date:  1999-04       Impact factor: 5.790

7.  Continuous infusion ceftazidime in intensive care: a randomized controlled trial.

Authors:  J Lipman; C D Gomersall; T Gin; G M Joynt; R J Young
Journal:  J Antimicrob Chemother       Date:  1999-02       Impact factor: 5.790

8.  Stability of meropenem in normal saline solution after storage at room temperature.

Authors:  Sutep Jaruratanasirikul; Somchai Sriwiriyajan
Journal:  Southeast Asian J Trop Med Public Health       Date:  2003-09       Impact factor: 0.267

Review 9.  Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid.

Authors:  William A Craig
Journal:  Infect Dis Clin North Am       Date:  2003-09       Impact factor: 5.982

Review 10.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

View more
  46 in total

1.  Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.

Authors:  Mahesh N Samtani; Robert Flamm; Koné Kaniga; Partha Nandy
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

2.  High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.

Authors:  Justin R Lenhard; Jürgen B Bulitta; Terry D Connell; Natalie King-Lyons; Cornelia B Landersdorfer; Soon-Ee Cheah; Visanu Thamlikitkul; Beom Soo Shin; Gauri Rao; Patricia N Holden; Thomas J Walsh; Alan Forrest; Roger L Nation; Jian Li; Brian T Tsuji
Journal:  J Antimicrob Chemother       Date:  2016-09-15       Impact factor: 5.790

3.  Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes.

Authors:  Rajnikant Sharma; Saloni Patel; Cely Abboud; John Diep; Neang S Ly; Jason M Pogue; Keith S Kaye; Jian Li; Gauri G Rao
Journal:  Int J Antimicrob Agents       Date:  2016-12-23       Impact factor: 5.283

4.  Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an In Vitro Pharmacokinetic/Pharmacodynamic Model.

Authors:  Xingchen Bian; Xiaofen Liu; Yuancheng Chen; Daijie Chen; Jian Li; Jing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

5.  After standard dosage of piperacillin plasma concentrations of drug are subtherapeutic in burn patients.

Authors:  Katharina Olbrisch; Tobias Kisch; Julia Thern; Evelyn Kramme; Jan Rupp; Tobias Graf; Sebastian G Wicha; Peter Mailänder; Walter Raasch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-10-27       Impact factor: 3.000

6.  Intravenous Push Administration of Antibiotics: Literature and Considerations.

Authors:  Samantha Spencer; Heather Ipema; Patricia Hartke; Courtney Krueger; Ryan Rodriguez; Alan E Gross; Michael Gabay
Journal:  Hosp Pharm       Date:  2018-03-08

Review 7.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

8.  Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients.

Authors:  Joan Antoni Schoenenberger-Arnaiz; Faten Ahmad-Diaz; Mar Miralbes-Torner; Ana Aragones-Eroles; Manuel Cano-Marron; Mercedes Palomar-Martinez
Journal:  Eur J Hosp Pharm       Date:  2019-02-27

9.  Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia.

Authors:  Anthony M Nicasio; Robert E Ariano; Sheryl A Zelenitsky; Aryun Kim; Jared L Crandon; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

10.  Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Pierre-François Laterre; Thierry Dugernier; Herbert Spapen; Isabelle Delattre; Xavier Wittebole; Daniel De Backer; Brice Layeux; Pierre Wallemacq; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2010-07-01       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.